Targacept Reports Positive Results for Potential Alzheimer's Drug
Posted May 19, 2006
WINSTON-SALEM, N.C. — A proposed drug for the treatment of Alzheimer's disease achieved positive results in a Phase II clinical trial,
reported this week.
The compound TC-1734 could be used as a treatment for age associated memory impairment. It was discovered by Targacept researchers utilizing a molecular design platform designed at Targacept.
Targacept is developing the drug along with AstraZeneca.
Patients in the trial between the ages of 50 and 80 who reported memory impairment without evidence of dementia were tested at 16 U.S. sites. Each received 25mg or 50mg doses of TC-1734 or placebo once a day for a period of 16 weeks. They were also administered memory tests.
Targacept said the three primary endpoints for the trial were achieved.
"These data may generate renewed optimism for many older persons who are challenged by memory and attention impairments that make their ordinary daily living tasks and social interactions difficult," said J. Donald deBethizy, chief executive officer of Targacept.